{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T13:31:55Z","timestamp":1790947915518,"version":"4.1.0"},"reference-count":103,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Biological Macromolecules"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.ijbiomac.2025.143838","type":"journal-article","created":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T11:34:21Z","timestamp":1746185661000},"page":"143838","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"P1","title":["The role of biological macromolecules in the regulation of angiogenesis in glioblastoma: Focus on vascular growth factors, integrins, and extracellular matrix proteins"],"prefix":"10.1016","volume":"311","author":[{"given":"Abbas","family":"Zabihi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijbiomac.2025.143838_bb0005","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.3390\/cancers14102412","article-title":"Epidemiology of glioblastoma multiforme\u2013literature review","volume":"14","author":"Grochans","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.ijbiomac.2025.143838_bb0010","first-page":"299","article-title":"Management of glioblastoma: state of the art and future directions","volume":"70","author":"Tan","year":"2020","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.ijbiomac.2025.143838_bb0015","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1188\/16.CJON.S1.2-8","article-title":"Glioblastoma: overview of disease and treatment","volume":"20","author":"Davis","year":"2016","journal-title":"Clin. J. Oncol. Nurs."},{"key":"10.1016\/j.ijbiomac.2025.143838_bb0020","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/s13311-016-0510-y","article-title":"New directions in anti-angiogenic therapy for glioblastoma","volume":"14","author":"Wang","year":"2017","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.ijbiomac.2025.143838_bb0025","doi-asserted-by":"crossref","first-page":"19059","DOI":"10.1073\/pnas.1318022110","article-title":"Improved tumor oxygenation and survival in glioblastoma patients who show increased blood perfusion after cediranib and chemoradiation","volume":"110","author":"Batchelor","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ijbiomac.2025.143838_bb0030","doi-asserted-by":"crossref","first-page":"112","DOI":"10.3390\/cancers14010112","article-title":"Frontiers in anti-cancer drug discovery: challenges and perspectives of metformin as anti-angiogenic add-on therapy in glioblastoma","volume":"14","author":"Guarnaccia","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.ijbiomac.2025.143838_bb0035","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s43046-021-00072-6","article-title":"Anti-angiogenesis in cancer therapeutics: the magic bullet","volume":"33","author":"Oguntade","year":"2021","journal-title":"J. Egypt. Natl. Cancer Inst."},{"key":"10.1016\/j.ijbiomac.2025.143838_bb0040","first-page":"252","article-title":"Glioblastoma: defining tumor niches, trends","volume":"1","author":"Hambardzumyan","year":"2015","journal-title":"Cancer"},{"key":"10.1016\/j.ijbiomac.2025.143838_bb0045","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1007\/s00401-016-1545-1","article-title":"The 2016 World Health Organization classification of tumors of the central nervous system: a summary","volume":"131","author":"Louis","year":"2016","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.ijbiomac.2025.143838_bb0050","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1002\/ijc.2910590415","article-title":"Vascular endothelial growth factor and glioma angiogenesis: coordinate induction of VEGF receptors, distribution of VEGF protein, and possible in vivo regulatory mechanisms","volume":"59","author":"Plate","year":"1994","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ijbiomac.2025.143838_bb0055","first-page":"1670","article-title":"Inhibition of vascular endothelial growth factor receptor signaling in glioma","volume":"21","author":"De Groot","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ijbiomac.2025.143838_bb0060","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1186\/1471-2407-9-444","article-title":"Concerns about anti-angiogenic treatment in patients with glioblastoma multiforme","volume":"9","author":"Verhoeff","year":"2009","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ijbiomac.2025.143838_bb0065","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1097\/CCO.0b013e32831186ba","article-title":"Antiangiogenic therapy in malignant gliomas","volume":"20","author":"Norden","year":"2008","journal-title":"Curr. Opin. Oncol."},{"key":"10.1016\/j.ijbiomac.2025.143838_bb0070","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1097\/00005072-199904000-00001","article-title":"Mechanisms of angiogenesis in the brain","volume":"58","author":"Plate","year":"1999","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"10.1016\/j.ijbiomac.2025.143838_bb0075","first-page":"813","article-title":"Antiangiogenic strategies in glioblastoma multiforme: an update","volume":"18","author":"Hamerla","year":"2018","journal-title":"Expert Rev. Anticancer Ther."},{"key":"10.1016\/j.ijbiomac.2025.143838_bb0080","first-page":"49","article-title":"Intracerebral hemorrhage after carotid ligation in tumor-bearing rats","volume":"7","author":"Brem","year":"1976","journal-title":"Stroke"},{"key":"10.1016\/j.ijbiomac.2025.143838_bb0085","first-page":"14626","article-title":"Dual inhibition of Ang-2 and VEGF receptors normalizes tumor vasculature and prolongs survival in glioblastoma by altering macrophages","volume":"109","author":"Peterson","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ijbiomac.2025.143838_bb0090","first-page":"6624","article-title":"Inhibition of glioma angiogenesis and growth in vivo by systemic treatment with a monoclonal antibody against vascular endothelial growth factor receptor-2","volume":"61","author":"Kunkel","year":"2001","journal-title":"Cancer Res."},{"key":"10.1016\/j.ijbiomac.2025.143838_bb0095","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1089\/wound.2013.0517","article-title":"Vascular endothelial growth factor and angiogenesis in the regulation of cutaneous wound repair","volume":"3","author":"Johnson","year":"2014","journal-title":"Adv. Wound Care"},{"key":"10.1016\/j.ijbiomac.2025.143838_bb0105","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1093\/neuonc\/nop027","article-title":"Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and mice","volume":"12","author":"De Groot","year":"2010","journal-title":"Neuro-Oncol."},{"key":"10.1016\/j.ijbiomac.2025.143838_bb0110","doi-asserted-by":"crossref","first-page":"4722","DOI":"10.1200\/JCO.2007.12.2440","article-title":"Bevacizumab plus irinotecan in recurrent glioblastoma multiforme","volume":"25","author":"Vredenburgh","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ijbiomac.2025.143838_bb0115","doi-asserted-by":"crossref","first-page":"5296","DOI":"10.1158\/0008-5472.CAN-09-0814","article-title":"A \u201cvascular normalization index\u201d as potential mechanistic biomarker to predict survival after a single dose of cediranib in recurrent glioblastoma patients","volume":"69","author":"Sorensen","year":"2009","journal-title":"Cancer Res."},{"key":"10.1016\/j.ijbiomac.2025.143838_bb0120","first-page":"304","article-title":"Tumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecan","volume":"28","author":"Sathornsumetee","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ijbiomac.2025.143838_bb0125","first-page":"827","article-title":"Safety and efficacy of erlotinib in first-relapse glioblastoma: a phase II open-label study","volume":"13","author":"Yung","year":"2011","journal-title":"Neuro-Oncol."},{"key":"10.1016\/j.ijbiomac.2025.143838_bb0130","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1200\/JCO.2009.23.2595","article-title":"Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma","volume":"28","author":"Wick","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ijbiomac.2025.143838_bb0135","first-page":"131","article-title":"Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastoma","volume":"110","author":"Reardon","year":"2012","journal-title":"J. Neurooncol"},{"key":"10.1016\/j.ijbiomac.2025.143838_bb0140","first-page":"1219","article-title":"Efficacy of depatuxizumab mafodotin (ABT-414) monotherapy in patients with EGFR-amplified, recurrent glioblastoma: results from a multi-center, international study","volume":"83","author":"Van den Bent","year":"2019","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.ijbiomac.2025.143838_bb0145","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1308573","article-title":"A randomized trial of bevacizumab for newly diagnosed glioblastoma","volume":"370","author":"Gilbert","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijbiomac.2025.143838_bb0150","doi-asserted-by":"crossref","first-page":"4085","DOI":"10.1200\/JCO.2013.49.6968","article-title":"Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial","volume":"31","author":"Gilbert","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ijbiomac.2025.143838_bb0155","first-page":"77","article-title":"Drugging the glioblastoma vascular niche","volume":"1","author":"Chheda","year":"2015","journal-title":"Trends Cancer"},{"key":"10.1016\/j.ijbiomac.2025.143838_bb0160","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1016\/j.ijrobp.2009.12.061","article-title":"Randomized double-blind placebo-controlled trial of bevacizumab therapy for radiation necrosis of the central nervous system","volume":"79","author":"Levin","year":"2011","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.ijbiomac.2025.143838_bb0165","first-page":"373","article-title":"AVAglio: phase 3 trial of bevacizumab plus temozolomide and radiotherapy in newly diagnosed glioblastoma multiforme","volume":"27","author":"Chinot","year":"2010","journal-title":"Adv. Ther."},{"key":"10.1016\/j.ijbiomac.2025.143838_bb0170","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJMoa1308345","article-title":"Bevacizumab plus radiotherapy\u2013temozolomide for newly diagnosed glioblastoma","volume":"370","author":"Chinot","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijbiomac.2025.143838_bb0175","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1200\/JCO.2008.16.3055","article-title":"Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma","volume":"27","author":"Kreisl","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ijbiomac.2025.143838_bb0180","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1016\/S1470-2045(14)70379-1","article-title":"Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a randomized, open-label, phase 3 trial","volume":"15","author":"Stupp","year":"2014","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ijbiomac.2025.143838_bb0185","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1056\/NEJMoa1707358","article-title":"Lomustine and bevacizumab in progressive glioblastoma","volume":"377","author":"Wick","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijbiomac.2025.143838_bb0190","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1186\/1471-2407-9-444","article-title":"Concerns about anti-angiogenic treatment in patients with glioblastoma multiforme","volume":"9","author":"Verhoeff","year":"2009","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ijbiomac.2025.143838_bb0195","first-page":"4291","article-title":"Immunobiology of gefitinib and implications for patient selection","volume":"68","author":"Reardon","year":"2008","journal-title":"Cancer Res."},{"key":"10.1016\/j.ijbiomac.2025.143838_bb0200","first-page":"655","article-title":"Stratified phase II trial of cetuximab in patients with recurrent high-grade glioma","volume":"21","author":"Neyns","year":"2010","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ijbiomac.2025.143838_bb0205","first-page":"353","article-title":"Cetuximab for recurrent high-grade gliomas: clinical experience and review of the literature","volume":"119","author":"Duerinck","year":"2019","journal-title":"Acta Neurol. Belg."},{"key":"10.1016\/j.ijbiomac.2025.143838_bb0215","first-page":"423","article-title":"Phase II study of crenolanib in recurrent glioblastoma","volume":"133","author":"Heiland","year":"2017","journal-title":"J. Neurooncol"},{"key":"10.1016\/j.ijbiomac.2025.143838_bb0220","first-page":"97","article-title":"A clinical trial of bevacizumab, temozolomide, and radiation for newly diagnosed glioblastoma","volume":"122","author":"Narayana","year":"2015","journal-title":"J. Neurosurg."},{"key":"10.1016\/j.ijbiomac.2025.143838_bb0225","first-page":"2070","article-title":"A phase II study of veliparib (ABT-888) and temozolomide (TMZ) in patients with newly diagnosed glioblastoma multiforme (GBM) with brain tumor initiating cells (BTIC) (NABTC 09-02)","volume":"30","author":"Desjardins","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ijbiomac.2025.143838_bb0230","first-page":"25664","article-title":"MGMT promoter methylation status as a predictive marker of response to temozolomide and radiotherapy in patients with newly diagnosed glioblastoma: a single institutional study","volume":"6","author":"Liang","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ijbiomac.2025.143838_bb0235","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1634\/theoncologist.11-2-152","article-title":"Therapeutic advances in the treatment of glioblastoma: rationale and potential role of targeted agents","volume":"11","author":"Reardon","year":"2006","journal-title":"Oncologist"},{"key":"10.1016\/j.ijbiomac.2025.143838_bb0240","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1200\/JCO.2008.16.3055","article-title":"Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma","volume":"27","author":"Kreisl","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ijbiomac.2025.143838_bb0245","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1056\/NEJMoa043331","article-title":"MGMT gene silencing and benefit from temozolomide in glioblastoma","volume":"352","author":"Hegi","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijbiomac.2025.143838_bb0250","first-page":"97","article-title":"MGMT testing\u2014the challenges for biomarker-based glioma treatment","volume":"8","author":"Wick","year":"2012","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.ijbiomac.2025.143838_bb0260","first-page":"1236","article-title":"Antiangiogenic therapy for glioblastoma","volume":"10","author":"Ghiaseddin","year":"2012","journal-title":"J. Natl. Compr. Canc. Netw."},{"key":"10.1016\/j.ijbiomac.2025.143838_bb0265","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJMoa1308345","article-title":"Bevacizumab plus radiotherapy\u2013temozolomide for newly diagnosed glioblastoma","volume":"370","author":"Chinot","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijbiomac.2025.143838_bb0270","first-page":"1198","article-title":"Phase II study of enzastaurin plus lomustine versus lomustine alone in patients with recurrent glioblastoma","volume":"35","author":"Wick","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ijbiomac.2025.143838_bb0280","first-page":"373","article-title":"AVAglio: phase 3 trial of bevacizumab plus temozolomide and radiotherapy in newly diagnosed glioblastoma multiforme","volume":"27","author":"Chinot","year":"2010","journal-title":"Adv. Ther."},{"key":"10.1016\/j.ijbiomac.2025.143838_bb0285","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma","volume":"352","author":"Stupp","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijbiomac.2025.143838_bb0290","first-page":"1","article-title":"Vascular epidermal growth factor (VEGF) in gliomas: biology and therapeutic targeting","volume":"16","author":"Wick","year":"2014","journal-title":"Neuro-Oncol"},{"key":"10.1016\/j.ijbiomac.2025.143838_bb0300","doi-asserted-by":"crossref","first-page":"4733","DOI":"10.1200\/JCO.2008.19.8721","article-title":"Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma","volume":"27","author":"Friedman","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ijbiomac.2025.143838_bb0305","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1200\/JCO.2008.16.3055","article-title":"Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma","volume":"27","author":"Kreisl","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ijbiomac.2025.143838_bb0310","first-page":"4291","article-title":"Immunobiology of gefitinib and implications for patient selection","volume":"68","author":"Reardon","year":"2008","journal-title":"Cancer Res."},{"key":"10.1016\/j.ijbiomac.2025.143838_bb0315","first-page":"29","article-title":"A phase II, randomized, non-comparative clinical trial of the effect of bevacizumab alone or in combination with irinotecan on 28-day mortality in patients with recurrent glioblastoma","volume":"90","author":"Cloughesy","year":"2008","journal-title":"J. Neurooncol"},{"key":"10.1016\/j.ijbiomac.2025.143838_bb0320","first-page":"945","article-title":"Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951","volume":"29","author":"Van den Bent","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ijbiomac.2025.143838_bb0325","doi-asserted-by":"crossref","first-page":"830","DOI":"10.3390\/cancers15030830","article-title":"Exploring the past, present, and future of anti-angiogenic therapy in glioblastoma","volume":"15","author":"Zhang","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.ijbiomac.2025.143838_bb0330","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma","volume":"352","author":"Stupp","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijbiomac.2025.143838_bb0335","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1093\/neuonc\/nop027","article-title":"Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and mice","volume":"12","author":"De Groot","year":"2010","journal-title":"Neuro-Oncol"},{"key":"10.1016\/j.ijbiomac.2025.143838_bb0340","first-page":"33","article-title":"Phase II study of metronomic chemotherapy for recurrent malignant gliomas in adults","volume":"11","author":"Kesari","year":"2009","journal-title":"Neuro-Oncol"},{"key":"10.1016\/j.ijbiomac.2025.143838_bb0345","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1093\/neuonc\/now009","article-title":"A Phase II randomized study of galunisertib monotherapy or galunisertib plus lomustine compared with lomustine monotherapy in patients with recurrent glioblastoma","volume":"18","author":"Brandes","year":"2016","journal-title":"Neuro-Oncol"},{"key":"10.1016\/j.ijbiomac.2025.143838_bb0350","first-page":"945","article-title":"Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951","volume":"29","author":"Van den Bent","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ijbiomac.2025.143838_bb0355","doi-asserted-by":"crossref","first-page":"7101","DOI":"10.1158\/1078-0432.CCR-07-1546","article-title":"Phase I trial of lenalidomide in patients with recurrent primary central nervous system tumors","volume":"13","author":"Fine","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ijbiomac.2025.143838_bb0360","first-page":"2720","article-title":"Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma","volume":"32","author":"Batchelor","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ijbiomac.2025.143838_bb0365","first-page":"213","article-title":"Phase II trial of erlotinib with temozolomide and radiation in patients with newly diagnosed glioblastoma multiforme","volume":"124","author":"Reardon","year":"2015","journal-title":"J. Neurooncol"},{"key":"10.1016\/j.ijbiomac.2025.143838_bb0370","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1007\/s12031-023-02099-x","article-title":"Anti-vascular endothelial growth factor therapy abolishes glioma-associated endothelial cell-induced tumor invasion","volume":"73","author":"Tang","year":"2023","journal-title":"J. Mol. Neurosci."},{"key":"10.1016\/j.ijbiomac.2025.143838_bb0375","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.981","article-title":"Preclinical anti-angiogenic and anti-cancer activities of BAY1143269 in glioblastoma via targeting oncogenic protein expression","volume":"10","author":"Wan","year":"2022","journal-title":"Pharmacol. Res. Perspect."},{"key":"10.1016\/j.ijbiomac.2025.143838_bb0380","first-page":"3522","article-title":"Impact of angiogenic inhibition in the treatment of newly diagnosed and recurrent glioblastoma: a meta-analysis based on randomized controlled trials","volume":"26","author":"Lan","year":"2022","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"10.1016\/j.ijbiomac.2025.143838_bb0385","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1002\/cbin.11859","article-title":"Novel targets to overcome antiangiogenesis therapy resistance in glioblastoma multiforme: systems biology approach and suggestion of therapy by galunisertib","volume":"46","author":"Hadizadeh","year":"2022","journal-title":"Cell Biol. Int."},{"key":"10.1016\/j.ijbiomac.2025.143838_bb0390","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.859633","article-title":"Next-generation anti-angiogenic therapies as a future prospect for glioma immunotherapy; from bench to bedside","volume":"13","author":"Shamshiripour","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ijbiomac.2025.143838_bb0395","first-page":"312","article-title":"Emerging roles of CircRNA-miRNA networks in cancer development and therapeutic response","volume":"9","author":"Hashemi","year":"2024","journal-title":"Non-coding RNA Res."},{"key":"10.1016\/j.ijbiomac.2025.143838_bb0400","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1200\/JCO.2008.17.5984","article-title":"Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034","volume":"27","author":"Van den Bent","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ijbiomac.2025.143838_bb0405","first-page":"630","article-title":"Tirapazamine plus cisplatin versus cisplatin in advanced non-small-cell lung cancer: a report of the international CATAPULT I study group","volume":"21","author":"Von Pawel","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ijbiomac.2025.143838_bb0410","first-page":"1236","article-title":"Antiangiogenic therapy for glioblastoma","volume":"10","author":"Ghiaseddin","year":"2012","journal-title":"J. Natl. Compr. Canc. Netw."},{"key":"10.1016\/j.ijbiomac.2025.143838_bb0415","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1167\/iovs.65.8.10","article-title":"Epithelial membrane protein 2 (EMP2) blockade attenuates pathological neovascularization in murine oxygen-induced retinopathy","volume":"65","author":"Aguirre","year":"2024","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.ijbiomac.2025.143838_bb0420","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1001\/jama.2014.7189","article-title":"Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib: the EVOLVE-1 randomized clinical trial","volume":"312","author":"Zhu","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.ijbiomac.2025.143838_bb0425","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.ccr.2006.11.021","article-title":"AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients","volume":"11","author":"Batchelor","year":"2007","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ijbiomac.2025.143838_bb0430","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1200\/JCO.2000.18.4.708","article-title":"Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas","volume":"18","author":"Fine","year":"2000","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ijbiomac.2025.143838_bb0435","first-page":"2817","article-title":"Phase II study of aflibercept in recurrent malignant glioma: a North American brain tumor consortium study","volume":"28","author":"De Groot","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ijbiomac.2025.143838_bb0440","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1200\/JCO.2009.26.3541","article-title":"Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group","volume":"28","author":"Wen","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ijbiomac.2025.143838_bb0445","first-page":"459","article-title":"High-grade gliomas","volume":"18","author":"Nayak","year":"2012","journal-title":"Continuum (Minneap. Minn.)"},{"key":"10.1016\/j.ijbiomac.2025.143838_bb0450","doi-asserted-by":"crossref","first-page":"4085","DOI":"10.1200\/JCO.2013.49.6968","article-title":"Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial","volume":"31","author":"Gilbert","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ijbiomac.2025.143838_bb0455","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1200\/JCO.2010.30.2729","article-title":"Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme","volume":"29","author":"Lai","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ijbiomac.2025.143838_bb0460","first-page":"3284","article-title":"Lessons from anti-vascular endothelial growth factor and anti-vascular endothelial growth factor receptor trials in patients with glioblastoma","volume":"30","author":"Lu-Emerson","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ijbiomac.2025.143838_bb0465","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1308573","article-title":"A randomized trial of bevacizumab for newly diagnosed glioblastoma","volume":"370","author":"Gilbert","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijbiomac.2025.143838_bb0470","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1200\/JCO.2008.16.3055","article-title":"Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma","volume":"27","author":"Kreisl","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ijbiomac.2025.143838_bb0475","doi-asserted-by":"crossref","first-page":"e188","DOI":"10.1200\/JCO.2009.26.9027","article-title":"Bevacizumab and recurrent malignant gliomas: a European perspective","volume":"28","author":"Wick","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ijbiomac.2025.143838_bb0480","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1200\/JCO.2009.26.3988","article-title":"Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma","volume":"28","author":"Batchelor","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ijbiomac.2025.143838_bb0485","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1056\/NEJMoa1707358","article-title":"Lomustine and bevacizumab in progressive glioblastoma","volume":"377","author":"Wick","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijbiomac.2025.143838_bb0490","first-page":"2035","article-title":"Non-coding RNAs targeting notch signaling pathway in cancer: from proliferation to cancer therapy resistance","volume":"209","author":"Hashemi","year":"2022","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.ijbiomac.2025.143838_bb0495","article-title":"Human papillomavirus infection and its relationship with common polymorphism of HLA gene by PCR method","volume":"31","author":"Hosseini","year":"2023","journal-title":"Gene Rep."},{"key":"10.1016\/j.ijbiomac.2025.143838_bb0500","doi-asserted-by":"crossref","first-page":"14","DOI":"10.53388\/PMR20230014","article-title":"Investigating the effect of rubiadin cytotoxicity and expression of BAX and BCL2 genes on HepG2 liver cancer cell line","volume":"5","author":"Pashapour","year":"2023","journal-title":"Precis. Med. Res."},{"key":"10.1016\/j.ijbiomac.2025.143838_bb0505","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/s13046-023-02640-1","article-title":"Protein disulfide-isomerase A4 confers glioblastoma angiogenesis promotion capacity and resistance to anti-angiogenic therapy","volume":"42","author":"Tu","year":"2023","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.ijbiomac.2025.143838_bb0510","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2023.112127","article-title":"Circadian regulator CLOCK promotes tumor angiogenesis in glioblastoma","volume":"42","author":"Pang","year":"2023","journal-title":"Cell Rep."},{"key":"10.1016\/j.ijbiomac.2025.143838_bb0515","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.trecan.2022.09.005","article-title":"Challenges in glioblastoma research: focus on the tumor microenvironment","volume":"9","author":"Bikfalvi","year":"2023","journal-title":"Trends Cancer"},{"key":"10.1016\/j.ijbiomac.2025.143838_bb0525","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12967-023-03936-8","article-title":"Proteomic analysis predicts anti-angiogenic resistance in recurred glioblastoma","volume":"21","author":"Jeon","year":"2023","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.ijbiomac.2025.143838_bb0555","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.canlet.2018.04.018","article-title":"Acetyl-L-carnitine is an anti-angiogenic agent targeting the VEGFR2 and CXCR4 pathways","volume":"429","author":"Baci","year":"2018","journal-title":"Cancer Lett."},{"key":"10.1016\/j.ijbiomac.2025.143838_bb0565","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1056\/NEJM197111182852108","article-title":"Tumor angiogenesis: therapeutic implications","volume":"285","author":"Folkman","year":"1971","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijbiomac.2025.143838_bb0570","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1053\/sonc.2002.37263","article-title":"Role of angiogenesis in tumor growth and metastasis","volume":"29","author":"Folkman","year":"2002","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.ijbiomac.2025.143838_bb0575","doi-asserted-by":"crossref","first-page":"4736","DOI":"10.1073\/pnas.0730843100","article-title":"Inhibition of plaque neovascularization reduces macrophage accumulation and progression of advanced atherosclerosis","volume":"100","author":"Moulton","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U. S. A."}],"container-title":["International Journal of Biological Macromolecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0141813025043909?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0141813025043909?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T11:14:53Z","timestamp":1782904493000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0141813025043909"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":103,"alternative-id":["S0141813025043909"],"URL":"https:\/\/doi.org\/10.1016\/j.ijbiomac.2025.143838","relation":{},"ISSN":["0141-8130"],"issn-type":[{"value":"0141-8130","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The role of biological macromolecules in the regulation of angiogenesis in glioblastoma: Focus on vascular growth factors, integrins, and extracellular matrix proteins","name":"articletitle","label":"Article Title"},{"value":"International Journal of Biological Macromolecules","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijbiomac.2025.143838","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"143838"}}